drugset / Trial / NCT00500318

A Study of Exercise Endurance and Lung Hyperinflation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT00500318

Phase 3 Completed 181 enrolled AstraZeneca
RandomizedParallel-groupTriple-blindTreatment

Summary

This study evaluated the effect of inhaled aclidinium bromide on exercise endurance and in reducing resting and dynamic lung hyperinflation in patients with moderate to severe COPD. It was 9 weeks in duration, consisting of; a 2-week run-in period, 6 weeks of double-blind treatment, and a 1-week follow-up phone call. All patients meeting the eligibility criteria were randomized to one of two treatment groups: aclidinium bromide or placebo.

Timeline

Start
2007-07
Primary completion
2008-12
Completion
2010-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Aclidinium Small molecule 200 ug Inhaled